APOBEC3A通过脱氨基作用抑制HBV复制

目的:研究APOBEC3A抑制HBV复制的分子机制。方法:首先在肝癌细胞HuH7中过表达APOBEC3A,通过MTT法检测了APOBEC3A对细胞毒性的影响;通过免疫荧光检测了APOBEC3A在细胞中的定位,通过IP试验进一步证实了APOBEC3A与病毒颗粒的相互作用;并通过ELISA,特异性荧光定量PCR检测了HBV复制的参数包括上清中HBsAg,病毒核心颗粒中HBV DNA以及核内的cccDNA的表达水平;最后通过3D PCR方法分析了核心颗粒中HBV DNA脱氨基作用。结果:过表达APOBEC3A对HuH7细胞毒性没有显著性差异;APOBEC3A主要位于细胞核,但APOBEC3A可以与病毒颗粒结合,在逆转录环节对HBV复制发生抑制作用;共转染HBV复制质粒和APOBEC3A表达质粒后,细胞上清中HBsAg,核心颗粒中的HBV DNA以及核内的cccDNA均显著下降;最后通过3D PCR和克隆测序表明核心颗粒中的HBV DNA负链发生了大量的G-A突变,同时正链也发生了较多的C-T突变。结论:APOBEC3A可与病毒颗粒结合,在HBV复制的逆转录环节可作用于HBV单链,发生脱氨基作用,从而抑制HBV的复制。     

SIRT3激动剂对乙肝病毒转录和复制的影响

该文探讨了SIRT3激动剂(Honokiol,HKL)对乙肝病毒(Hepatitis B virus,HBV)转录和复制的影响。培养HepG2-NTCP和人原代肝细胞(primary human hepatocytes,PHH),感染HBV颗粒后,用Honokiol(5μmol/L、10μmol/L、20μmol/L)处理细胞后继续培养10天,通过荧光定量PCR检测细胞内HBV DNA、cccDNA和HBV RNAs水平,Southern blot实验进一步检测胞内HBV DNA水平。构建SIRT3-KO细胞,检测敲除SIRT3后,Honokiol对细胞内HBV DNA、cccDNA和HBV RNAs的影响。通过小鼠尾静脉高压注射pCMV-KRAB-Cre质粒和precccDNA质粒构建持续感染小鼠模型,一周后腹腔注射Honokiol持续20天。荧光定量PCR检测小鼠血清中HBV DNA拷贝数,肝组织内HBV DNA、cccDNA和HBV RNAs水平。结果表明,Honokiol浓度依赖性地抑制HepG2-NTCP和PHH细胞内HBV DNA以及HBV RNAs水平,此外,Honokiol可以降低cccDNA的转录活性;敲除SIRT3后,Honokiol不能发挥抗病毒作用;小鼠模型中,Honokiol能够降低血清中HBV DNA和肝组织内HBV DNA拷贝数,以及能够显著抑制肝组织内HBV RNAs水平和cccDNA的转录活性。该研究结果表明,Honokiol能够抑制乙肝病毒转录和复制。     

应用微环DNA技术体外诱导和制备重组的乙型肝炎病毒共价闭合环状DNA

乙型肝炎病毒(hepatitis B virus,HBV)共价闭合环状DNA(covalently closed circular DNA,cccDNA)是病毒慢性感染的分子基础。本课题组前期研究通过Cre/loxP介导的位点特异性DNA重组策略,在细胞核内由前体质粒诱导重组cccDNA(rcccDNA^loxP)产生,首次建立了HBV cccDNA的体外培养细胞和小鼠实验模型。本研究基于大肠埃希菌ZYCY10P3S2T PhiC31重组酶诱导表达系统,建立了一种体外诱导HBV rcccDNA(rcccDNA^attR)微环产生和纯化的策略。纯化的rcccDNA^attR微环具有超螺旋结构,细胞培养实验证实其能支持功能性的HBV复制和抗原表达。与普通的线性HBV复制子编码质粒相比,rcccDNA^attR尾静脉高压注射小鼠模型能诱导显著延长的病毒抗原血症。因此,本研究在原核表达系统和实验小鼠水平提供了一种更为简化的HBV cccDNA实验模型系统,并再次显示rcccDNA具有显著的稳定性,能作为一种基本策略在小鼠模型中诱导病毒持续感染。     

化学发光法检测体外HBV复制

目的:建立化学发光法检测体外HBV复制水平的方法,研究其灵敏度和稳定性.方法:用HBV DNA重组质粒pCH9转染到人肝癌细胞株HepG2和Huh7中,5d后收集细胞并抽提其HBV复制中问体DNA,转印后以地高辛标记HBV DNA为探针进行杂交,用化学发光法检测杂交结果,同时进行探针灵敏度的检测.结果:转染后HepG2和Huh7细胞提取HBV DNA中检测出较强的复制中间体的信号,分别为松散环状DNA(rcDNA),双链线性DNA(dslDNA),单链DNA(ssDNA),探针检测的灵敏度可达到lpg,接近同位素法检测的灵敏度.整个实验重复3次获得同样结果.结论:成功建立了稳定的化学发光法检测体外HBV复制水平的方法.     

重访乙型肝炎病毒感染肾脏的意义

乙型肝炎病毒(hepatitis B virus,HBV)嗜肝性主要由病毒与受体作用的特异性、支持共价闭合环状DNA(covalently closed circular DNA,cccDNA)形成的宿主因子和促进病毒RNA转录的核因子3种因素决定。人的肾脏很可能也提供这些要素,且许多研究发现HBV感染标记存在于慢性乙型肝炎患者的肾脏细胞中。本文探讨了HBV感染肾脏的可能性。由于目前血清乙型肝炎表面抗原(hepatitis B surface antigen,HBsAg)消失是功能性治愈慢性乙型肝炎的关键指标,如果肾脏也是HBV感染、表达和复制的另一靶器官,则肾脏在功能性治愈慢性乙型肝炎中的作用不可忽视。     

小剂量DNA毒剂诱导SV40转化的人细胞中的SV40DNA的增强复制

本文介绍了用~(32)P标记的pSV_2质粒为探针,通过DNA分子原位杂交研究小剂量DNA毒剂诱导被SV40转化的人细胞NB—E中SV40DNA的增强复制.最佳条件下,最大增强比可达4-5.而且,这种病毒DNA增强复制与病毒的增强复活与增强致突有相似的动力学过程和剂量响应关系.此结果为哺乳类细胞中可能存在SOS功能提供了进一步证据.被诱导细胞的Hirt沉淀与Hirt上清液中都存在SV40DNA片段,且Hirt上清液中SV40DNA片段大小均一,反映此过程与λ原噬菌体的诱导的起始过程有相似之处.小剂量紫外线可诱导被SV40转化的人XP细胞中的SV40 DNA的增强复制.说明这一诱导过程可能与切除修复功能有不同的遗传学过程.     

乙型肝炎病毒共价键闭环DNA的表观遗传调控研究进展

乙型肝炎病毒(hepatitis B virus,HBV)感染仍然是威胁全球人类生命与健康的重要危险因素。虽然目前的抗病毒治疗药物在控制乙型肝炎进展有显著疗效,但却始终无法达到根治HBV感染的目标。HBV共价闭合环状DNA(HBV cccDNA)是HBV转录复制的原始模板,也是HBV持续感染的关键因素。但由于缺少有效的完全清除HBV cccDNA的治疗方法,慢性乙型肝炎患者需长期服药以防治疗后停药复发。研究证实HBV cccDNA的转录受表观遗传机制调控,其中cccDNA甲基化、组蛋白修饰、miRNA、染色质重塑等均影响HBV cccDNA的功能。本文就HBV表观遗传调控的最新研究进展进行综述。     

NIRF对HBV复制的影响及其对组蛋白H3乙酰化水平的修饰

为研究NIRF(Np95/ICBP-90 like RING finger protein)对乙型肝炎病毒(hepatitis B virus,HBV)的复制以及与乙型肝炎病毒共价环状闭合DNA(HBV cccDNA)结合的组蛋白H3乙酰化的影响,采用脂质体转染将pGEM-HBV1.3+pFLAG、pGEM-HBV1.3+pFLAG-NIRF、pGEM-HBV1.3质粒分别转入HepG2细胞,Western blot检测NIRF蛋白的表达,用ELISA结合RT-PCR检测HBsAg、HBeAg以及HBV cccDNA的量并同时说明HBV在细胞内是完成完整复制表达的,采用染色质免疫共沉淀(ChIP)的方法检测与HBV cccDNA结合的组蛋白H3以及H3乙酰化水平的动态变化。结果显示,NIRF蛋白下调HBV标志物HBeAg、HBsAg的分泌以及HBV cccDNA的表达,表明其对HBV复制具有抑制作用;组蛋白H3及乙酰化的组蛋白H3都与HBV cccDNA的动态变化水平呈现相似的平行性,而NIRF蛋白也明显抑制组蛋白H3的表达水平和乙酰化水平。结论证实NIRF不仅能抑制HBV在肝癌细胞中的复制,而且能下调与HBV cccDNA结合的组蛋白H3和乙酰化组蛋白H3的表达。期待NIRF能为后续的HBV致病机理、HBV复制表观遗传学水平研究及有效抗病毒药物的研究与开发提供理论上的支持与帮助。     

CRL4在增殖的肝细胞系中上调乙型肝炎病毒抗原的分泌表达

乙型肝炎病毒（hepatitis B virus,HBV）编码的X蛋白（hepatitis B virus X protein,HBx）对HBV感染的起始和维持至关重要。HBx可能作为病毒来源的接头分子,介导Cullin-RING E3泛素连接酶4（cullin-RING ubiquitin E3 ligase 4,CRL4）复合物对染色体外DNA限制因子SMC5/6的降解。最近研究发现CRL4接头分子DNA损伤结合蛋白1（DNA damage-binding protein 1,DDB1）可不依赖与HBx的相互作用而直接上调病毒的表达和复制。本研究基于HBx基因删除（X-null）的HBV重组cccDNA（recombinant covalently closed circular DNA,rcccDNA）模型系统,在多种体外培养肝细胞系中证实上述发现。有意思的是,CRL4刺激rcccDNA^X-null转染细胞抗原分泌表达的效应能被血清饥饿实验抵消。应用尾静脉高压注射小鼠模型,同样发现CRL4并不上调rcccDNA^X-null在非增殖小鼠肝脏细胞中的表达。以上结果提示,细胞增殖特征与CRL4不依赖HBx上调病毒抗原表达的效应密切相关,有助于HBx生物学意义的准确分析和理解。     

人乳头状瘤病毒复制机制的研究进展

人乳头状瘤病毒(human papillomavirus,HPV)DNA以游离和整合两种形式存在于感染细胞中。游离形式HPVs的复制依赖于上皮细胞的分化,病毒E1、E2蛋白和复制起始位点(origin,Ori)为复制必需元件,E1和E2蛋白与Ori结合起始病毒DNA的复制。随后,病毒DNA通过E2蛋白与Brd4(bromodomain-containing protein 4)等细胞蛋白的互作而与染色体结合,并随细胞分裂平均分配到子代细胞中。在肿瘤中,高危型HPVs的基因组通常以整合形式存在,并随细胞的增殖而复制。     

Simple preparation of parapoxvirus genome DNA for endonuclease analysis

We compared five methods for improved extraction of very-large parapoxvirus DNA from infected cells: (i) alkaline-lysis procedure followed by phenol extraction; (ii) modified Hirt procedure, which was a neutral lysis procedure followed by phenol extraction; (iii) Hirt procedure; (iv) method used for extraction of vaccinia virus DNA; and (v) standard procedure using virus purification with an ultracentrifuge and protease-sodium dodecyl sulfate-phenol treatment. The alkaline-lysis procedure was more rapid, inexpensive and simpler than the other methods. Moreover, with this method it is not necessary to prepare any special facilities, reagents and kits. Although the extracted DNA was still crude, we could reproducibly prepare viral DNA from 2 X 10(6) infected cells in less than 2 hr and it could be readily digested by restriction endonuclease. This method will aid rapid genetic classification of parapoxvirus.     

Formation of covalently closed circular DNA in Hep38.7-Tet cells,a tetracycline inducible hepatitis B virus expression cell line

Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) plays a central role in chronic HBV infection. However, analysis of the molecular mechanism of cccDNA formation is difficult because of the low efficiency in tissue cultured cells. In this study, we developed a more efficient cccDNA expression cell, Hep38.7-Tet, by subcloning from a tetracycline inducible HBV expression cell, HepAD38. Higher levels of cccDNA were produced in Hep38.7-Tet cells compared to HepAD38 cells. In Hep38.7-Tet cells, the cccDNA was detectable at six days after HBV induction. HBV e antigen (HBeAg) secretion was dependent upon cccDNA production. We screened chemical compounds using Hep38.7-Tet cells and HBeAg secretion as a marker. Most of the hit compounds have already been reported as anti-HBV compounds. These data suggested that Hep38.7-Tet cells will be powerful tools for analysis of the molecular mechanism of cccDNA formation/maintenance and development of novel therapeutic agents to control HBV infection.     

Concerted action of activation-induced cytidine deaminase and uracil-DNA glycosylase reduces covalently closed circular DNA of duck hepatitis B virus

Covalently closed circular DNA (cccDNA) forms a template for the replication of hepatitis B virus (HBV) and duck HBV (DHBV). Recent studies suggest that activation-induced cytidine deaminase (AID) functions in innate immunity, although its molecular mechanism of action remains unclear, particularly regarding HBV restriction. Here we demonstrated that overexpression of chicken AID caused hypermutation and reduction of DHBV cccDNA levels. Inhibition of uracil-DNA glycosylase (UNG) by UNG inhibitor protein (UGI) abolished AID-induced cccDNA reduction, suggesting that the AID/UNG pathway triggers the degradation of cccDNA via cytosine deamination and uracil excision.     

Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus

Covalently closed circular DNA (cccDNA), the nuclear form of hepatitis B virus (HBV), is synthesized by repair of the relaxed circular (RC) DNA genome. Initially, cccDNA is derived from RC DNA from the infecting virion, but additional copies of cccDNA are derived from newly synthesized RC DNA molecules in a process termed intracellular amplification. It has been shown that the large viral envelope protein limits the intracellular amplification of cccDNA for duck hepatitis B virus. The role of the envelope proteins in regulating the amplification of cccDNA in HBV is not well characterized. The present report demonstrates regulation of synthesis of cccDNA by the envelope proteins of HBV. Ablation of expression of the envelope proteins led to an increase (>6-fold) in the level of cccDNA. Subsequent restoration of envelope protein expression led to a decrease (>50%) in the level of cccDNA, which inversely correlated with the level of the envelope proteins. We found that the expression of L protein alone or in combination with M and/or S proteins led to a decrease in cccDNA levels, indicating that L contributes to the regulation of cccDNA. Coexpression of L and M led to greater regulation than either L alone or L and S. Coexpression of all three envelope proteins was also found to limit completion of plus-strand DNA synthesis, and the degree of this effect correlated with the level of the proteins and virion secretion.     

Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients

Hepatitis B virus (HBV) cccDNA levels is an absolute marker of HBV replication in the liver of HBV infected patients. This study aimed to quantify the HBV cccDNA levels in sera and liver tissue samples of treatment naïve patients with chronic hepatitis B. Eighty one chronic hepatitis B (CHB) treatment naïve patients were enrolled from January 2009 to June 2011. Total HBV DNA and HBV cccDNA levels were quantified using sensitive real time PCR assay. The mean age of recruited patients was 34 ± 11.5 years. Fifty four (66.7 %) patients were HBeAg negative. Liver tissue samples were available from 2 HBeAg positive and 21 HBeAg negative CHB patients. The amount of total intrahepatic HBV DNA ranged from 0.09 to 1508.92 copies/cell. The median intrahepatic HBV cccDNA was 0.31 and 0.20 copies/cell in HBeAg positive and HBeAg negative cases, respectively. Serum HBV cccDNA was detectable in 85.2 % HBeAg positive and 48.1 % HBeAg negative CHB patients. Median serum HBV cccDNA was 46,000 and 26,350 copies/mL in HBeAg positive and HBeAg negative subjects, respectively. There was a significant positive correlation between the levels of intrahepatic total HBV DNA and intrahepatic HBV cccDNA (r = 0.533, p = 0.009). A positive correlation was also seen between serum HBV cccDNA levels and serum HBV DNA levels (r = 0.871, p < 0.001). It was concluded that serum HBV cccDNA could be detectable in higher proportion of HBeAg positive patients compared to HBeAg negative patients. Moreover, the median level of serum HBV cccDNA was significantly higher in HBeAg positive patients in contrast to HBeAg negative subjects.     

Effects of Entecavir on Hepatitis B Virus Covalently Closed Circular DNA in Hepatitis B e Antigen-Positive Patients with Hepatitis B

The aim of this study was to assess the effect of 48-week entecavir therapy on serum and intrahepatic hepatitis B virus, covalently closed circular DNA (HBV cccDNA) levels in hepatitis B e antigen (HBeAg)-positive patients. A total of 120 patients with HBeAg-positive chronic hepatitis were treated with entecavir for 48 weeks. Serum HBV markers, total HBV DNA, and HBV cccDNA levels were measured at baseline and week 48. Biopsies from 20 patients were available for both intrahepatic total HBV DNA and cccDNA testing at these timepoints. HBV cccDNA levels were decreased from a median level of 5.1×10⁶ copies/mL at baseline to a median level of 2.4×10³ copies/mL at week 48. Reduction magnitudes of HBV cccDNA in patients with normalized alanine aminotransferase levels and those undergoing HBeAg seroconversion were significantly greater than those in alanine aminotransferase-abnormal and HBeAg positive patients. Intrahepatic HBV cccDNA was decreased significantly after 48 weeks of treatment, but could not be eradicated. In conclusion, treatment of HBeAg-positive hepatitis B patients with entecavir for 48 weeks decreased serum and intrahepatic HBV cccDNA significantly, and the magnitude of HBV cccDNA reduction was related to total HBV DNA decrease, alanine aminotransferase normalization, and HBeAg seroconversion.     

Generation of Covalently Closed Circular DNA of Hepatitis B Viruses via Intracellular Recycling Is Regulated in a Virus Specific Manner

Persistence of hepatitis B virus (HBV) infection requires covalently closed circular (ccc)DNA formation and amplification, which can occur via intracellular recycling of the viral polymerase-linked relaxed circular (rc) DNA genomes present in virions. Here we reveal a fundamental difference between HBV and the related duck hepatitis B virus (DHBV) in the recycling mechanism. Direct comparison of HBV and DHBV cccDNA amplification in cross-species transfection experiments showed that, in the same human cell background, DHBV but not HBV rcDNA converts efficiently into cccDNA. By characterizing the distinct forms of HBV and DHBV rcDNA accumulating in the cells we find that nuclear import, complete versus partial release from the capsid and complete versus partial removal of the covalently bound polymerase contribute to limiting HBV cccDNA formation; particularly, we identify genome region-selectively opened nuclear capsids as a putative novel HBV uncoating intermediate. However, the presence in the nucleus of around 40% of completely uncoated rcDNA that lacks most if not all of the covalently bound protein strongly suggests a major block further downstream that operates in the HBV but not DHBV recycling pathway. In summary, our results uncover an unexpected contribution of the virus to cccDNA formation that might help to better understand the persistence of HBV infection. Moreover, efficient DHBV cccDNA formation in human hepatoma cells should greatly facilitate experimental identification, and possibly inhibition, of the human cell factors involved in the process.